Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 USD | -4.11% | -8.20% | 0.00% |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 604M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -199M | EV / Sales 2024 * | 109 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 92.4 x |
P/E ratio 2024 * |
-4.4
x | P/E ratio 2025 * |
-3.54
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | -4.11% | ||
1 week | -8.20% | ||
Current month | -7.53% | ||
1 month | -38.54% | ||
3 months | -53.22% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 14 | -4.11% | 217,579 |
24-05-09 | 14.6 | +15.32% | 280,449 |
24-05-08 | 12.66 | -7.25% | 423,239 |
24-05-07 | 13.65 | -2.22% | 251,900 |
24-05-06 | 13.96 | -8.46% | 238,284 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 604M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- KYTX Stock